In the recent *Lancet* Series on tuberculosis elimination, Courtney Yuen and colleagues (Dec 5, pp 2334–43) proffer a strong argument for active case finding as a means to reduce *Mycobacterium tuberculosis* transmission. However, the evidence in support of such an argument is scarce.

No randomised controlled study has yet convincingly shown a population-level effect of active case finding on *M tuberculosis* transmission. The two clinical trials referred to by Yuen and colleagues fit into the category of contact investigation. Results of these studies are inconclusive at best. The ZAMSTAR study compared enhanced case finding, a household intervention, both, or neither. Enhanced case finding included community mobilisation, symptom screening during mobile outreach activities, and easy access to sputum collection. The household intervention, aimed at households of patients with tuberculosis, included three visits for education and screening for tuberculosis and HIV, and latent tuberculosis treatment. Whereas the household intervention showed non-significant effects on both adult tuberculosis prevalence and incidence of infection in school children, enhanced case finding had no effect on either endpoint. In Brazil, intervention communities received a contact investigation package, resulting in reduced tuberculosis notifications. However, the effect attributable to the active case finding component of these two interventions is impossible to assess.

The cited multisite assessment of TB REACH projects included a summary assessment of notification rates across diverse interventions to improve tuberculosis detection, including improved diagnostics, demand
generation, private sector engagement, and various active case finding approaches. Most projects included a combination of interventions, making assessment of the contribution of active case finding difficult.

With little evidence of a population-level effect on transmission, the primary objective of active case finding should be to improve health outcomes among screened individuals. The principles of screening include a careful balancing of the benefits and risks, including false positive diagnosis. As a result, WHO strongly recommends systematic screening in three risk groups: tuberculosis contacts, people with HIV/AIDS, and people exposed to silica dust. In most settings, the size of these risk groups is small, and such targeted screening would therefore contribute only marginally to overall tuberculosis detection.

The epidemiology and health-system context needs to guide prioritisation of other risk groups to be screened systematically. Mass screening should be avoided, and active case finding in risk groups with moderately increased tuberculosis risk should be done with great caution, while minimising risk of false positive diagnosis. Any implementation of a screening strategy needs to be paired with assessment to ensure cost-effectiveness and minimise risk of harm.

HA reports grants from Bill and Melinda Gates Foundation and the US National Institutes of Health, and this Correspondence is in response to a published Article that quoted some of our previous work.

*Katharina Kranzer, Palwasha Khan, Peter Godfrey-Fausset, Helen Ayles, Knut Lönnroth
katharina.kranzer@lshtm.ac.uk

National Mycobacterium Reference Laboratory, Research Centre Borstel, Germany (KK); Department of Infectious Disease Epidemiology (KK, PK) and Department of Clinical Research (PG-F, HA), London School of Hygiene and Tropical Medicine, London, UK; Department of Infection and Immunity, Royal
London Hospital, Barts Health NHS Trust, London, UK (PK); Zambart, Lusaka, Zambia (HA); and Global TB Programme, World Health Organization, Geneva, Switzerland (KL)


